← 返回

大 B 细胞淋巴瘤微环境原型图谱

英文原题:Large B cell lymphoma microenvironment archetype profiles.

查看英文原题

Large B cell lymphoma microenvironment archetype profiles.

PubMed 2025/06/18(内容时间) Cancer Cell Q1 · IF 56.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

大B细胞淋巴瘤(LBCL)是一组临床和生物学异质性很强的淋巴恶性肿瘤,其复杂微环境是疾病发生发展的核心因素。本研究对232份肿瘤及对照活检样本进行单核多组学分析,以表征LBCL肿瘤中的多种细胞类型和亚群,有效捕捉淋巴系、髓系及非造血细胞区室。不同细胞亚群以具有典型特征的淋巴瘤微环境原型(LymphoMAP)模式共同出现,分为:(1)T细胞稀少,癌症相关成纤维细胞和肿瘤相关巨噬细胞比例较高(FMAC);(2)具有淋巴结结构细胞类型,并含有初始和记忆T细胞(LN);或(3)活化巨噬细胞和耗竭CD8+ T细胞(TEX)。不同的细胞间通讯模式构成了这些原型细胞亚群的转录表型,分别导致T细胞被排斥、得到支持或受到抑制。与此一致,不同LymphoMAP模式与接受CD19嵌合抗原受体(CAR)T细胞治疗后的临床结局显著相关。

展开英文摘要原文

Large B cell lymphomas (LBCL) are clinically and biologically heterogeneous lymphoid malignancies with complex microenvironments that are central to disease etiology.

Here, we have employed single-nucleus multiome profiling of 232 tumor and control biopsies to characterize diverse cell types and subsets that are present in LBCL tumors, effectively capturing the lymphoid, myeloid, and non-hematopoietic cell compartments. Cell subsets co-occurred in stereotypical lymphoma microenvironment archetype profiles (LymphoMAPs) defined by; (1) a sparsity of T cells and high frequencies of cancer-associated fibroblasts and tumor-associated macrophages (FMAC); (2) lymph node architectural cell types with naive and memory T cells (LN); or (3) activated macrophages and exhausted CD8 + T cells (TEX).

Divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets resulting in exclusion, support, or suppression of T cells, respectively. Consistent with this, LymphoMAPs were associated with significantly different clinical outcomes following CD19 chimeric antigen receptor (CAR) T cell therapy.

论文信息

作者
Li X、Singhal K、Deng Q、Chihara D、Russler-Germain D、Harkins RA、Henderson J、Arita K
第一作者单位
Department of Lymphoma and Myeloma, University of Texas (UT) MD Anderson Cancer Center, Houston, TX, USA; Lymphoid Malignancies Program, UT MD Anderson Cancer Center, Houston, TX, USA.United States
通讯作者单位
Department of Lymphoma and Myeloma, University of Texas (UT) MD Anderson Cancer Center, Houston, TX, USA; Lymphoid Malignancies Program, UT MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mgreen5@mdanderson.org.United States
期刊
Cancer cell2025 Jul 14
原文标识
PubMed 40920660 · DOI 10.1016/j.ccell.2025.06.002